New Therapy for Metastatic Prostate Cancer Targets PSMA
There’s an exciting new development in treating metastatic prostate cancer (PCa) that no longer responds to hormone therapy. Such cancer is clinically called metastatic castration-resistant prostate cancer, or mCRPC. There is currently no cure when PCa reaches this stage, but new drugs and immunotherapies can prolong life. Researchers are exploring and testing therapies that destroy keep reading